The Native Antigen Company (NAC) has announced the release of its Dengue Virus serotype 2 NS1 protein (DENV2 NS1).
NAC’s DENV2 NS1 has been manufactured in response to the unmet need for a highly purified, concentrated protein for use in vaccine development and serological based diagnostic assays.
To achieve this, the company has employed its novel VirTuE™ platform which is based entirely on human cell lines using expression techniques.
The resultant DENV2 NS1 proteins are purified to a high degree, are in their native folding state, and possess all post-translational modifications. This advanced approach offers a product which delivers optimal antigenicity.
With more than one-third of the world’s population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics.
As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are not yet any vaccines to prevent infection with dengue virus.
NAC is currently developing DENV1, DENV3 and DENV4 to cover the full spectrum of serotypes.